School of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada.
PLoS Pathog. 2020 Aug 6;16(8):e1008696. doi: 10.1371/journal.ppat.1008696. eCollection 2020 Aug.
HLA-B35Px is associated with HIV-1 disease rapid progression to AIDS. However, the mechanism(s) underlying this deleterious effect of this HLA allele on HIV-1 infection outcome has not fully understood. CD8+ T cells play a crucial role to control the viral replication but impaired CD8+ T cells represent a major hallmark of HIV-1 infection. Here, we examined the effector functions of CD8+ T cells restricted by HLA-B35Px (HLA-B35:03 and HLA-B35:02), HLA-B27/B57 and non-HLA-B27/B57 (e.g. HLA-A01, A02, A03, A11, A24, A26, B40, B08, B38, B44). CD8+ T cells restricted by HLA-B35Px exhibited an impaired phenotype compared with those restricted by HLA-B27/B57 and even non-HLA-B27/B57. CD8+ T cells restricted by non-HLA-B27/B57 when encountered their cognate epitopes upregulated TIM-3 and thus became suppressed by regulatory T cells (Tregs) via TIM-3: Galectin-9 (Gal-9). Strikingly, CD8+ T cells restricted by HLA-B35Px expressed fewer TIM-3 and therefore did not get suppressed by Tregs, which was similar to CD8+ T cells restricted by HLA-B27/B57. Instead, CD8+ T cells restricted by HLA-B35Px upon recognition of their cognate epitopes upregulated CTLA-4. The transcriptional and impaired phenotype (e.g. poor effector functions) of HIV-specific CD8+ T cells restricted by HLA-B35 was related to persistent CTLA-4, elevated Eomes and blimp-1 but poor T-bet expression. As such, anti-CTLA-4 antibody, Ipilimumab, reversed the impaired proliferative capacity of antigen-specific CD8+ T cells restricted by HLA-B35Px but not others. This study supports the concept that CD8+ T resistance to Tregs-mediated suppression is related to allele restriction rather than the epitope specificity. Our results aid to explain a novel mechanism for the inability of HIV-specific CD8+ T cells restricted by HLA-B35Px to control viral replication.
HLA-B35Px 与 HIV-1 疾病快速进展为艾滋病有关。然而,这种 HLA 等位基因对 HIV-1 感染结果的有害影响的机制尚未完全理解。CD8+T 细胞在控制病毒复制方面起着至关重要的作用,但 CD8+T 细胞受损是 HIV-1 感染的主要标志之一。在这里,我们研究了受 HLA-B35Px(HLA-B35:03 和 HLA-B35:02)、HLA-B27/B57 和非 HLA-B27/B57(例如 HLA-A01、A02、A03、A11、A24、A26、B40、B08、B38、B44)限制的 CD8+T 细胞的效应功能。与受 HLA-B27/B57 限制的 CD8+T 细胞相比,受 HLA-B35Px 限制的 CD8+T 细胞表现出受损的表型,甚至与不受 HLA-B27/B57 限制的 CD8+T 细胞相比也是如此。当遇到其同源表位时,受非 HLA-B27/B57 限制的 CD8+T 细胞上调 TIM-3,从而通过 TIM-3:Galectin-9(Gal-9)被调节性 T 细胞(Tregs)抑制。引人注目的是,受 HLA-B35Px 限制的 CD8+T 细胞表达较少的 TIM-3,因此不会被 Tregs 抑制,这与受 HLA-B27/B57 限制的 CD8+T 细胞相似。相反,受 HLA-B35Px 限制的 CD8+T 细胞在识别其同源表位时上调 CTLA-4。受 HLA-B35 限制的 HIV 特异性 CD8+T 细胞的转录和受损表型(例如,效应功能差)与持续的 CTLA-4、升高的 Eomes 和 Blimp-1 但 poor T-bet 表达有关。因此,抗 CTLA-4 抗体 Ipilimumab 逆转了受 HLA-B35Px 限制的抗原特异性 CD8+T 细胞的增殖能力受损,但对其他细胞没有作用。这项研究支持这样一种概念,即 CD8+T 细胞对 Tregs 介导的抑制的抗性与等位基因限制有关,而不是与表位特异性有关。我们的研究结果有助于解释 HLA-B35Px 限制的 HIV 特异性 CD8+T 细胞无法控制病毒复制的一种新机制。